FDA grants important designation to Radiopharm Theranostics' DUNP19 technology

September 19, 2022 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Radiopharm Theranostics (ASX:RAD) has announced that the US FDA has granted Rare Pediatric Disease Designation for its DUNP19 technology for the treatment of osteosarcoma. …

Subscribe now to continue reading.

Latest Video

PBAC agenda reflects increasing number of companies seeking revised recommendations
March 25, 2026 - Latest News
Australia moves closer to Europe as health and research ties deepen under landmark agreement
March 25, 2026 - Latest News
Small changes can still become foundations for the meaningful, but understand how decisions are made
March 25, 2026 - Latest News
Auditor General proposes possible reviews of new Centre for Disease Control
March 24, 2026 - Latest News
Faster FDA pathway approves new higher dose weight loss therapy in just 54 days
March 25, 2026 - Latest News

FDA grants important designation to Radiopharm Theranostics' DUNP19 technology

This is a preview of subscriber content

Latest Video

Most Read

PBAC agenda reflects increasing number of companies seeking revised recommendations

Australia moves closer to Europe as health and research ties deepen under landmark agreement

Small changes can still become foundations for the meaningful, but understand how decisions are made

Auditor General proposes possible reviews of new Centre for Disease Control

Faster FDA pathway approves new higher dose weight loss therapy in just 54 days

New Stories

The 'Dispatched' Week in Review' Podcast - 27 March

The unseen price of survival for women facing early breast cancer in Australia

This is the not so quiet demand and doctrine of rationed health care

If these can be presented as positives, then we really have become accustomed to terrible

Liberty expands into Asia Pacific life sciences insurance with new tailored offering

Budget delivers progress, but hundreds of thousands still waiting for access

To what extent does the system even see itself as bound by external review?

Sign In

FDA grants important designation to Radiopharm Theranostics' DUNP19 technology

This is a preview of subscriber content

Latest Video

Most Read

PBAC agenda reflects increasing number of companies seeking revised recommendations

Australia moves closer to Europe as health and research ties deepen under landmark agreement

Small changes can still become foundations for the meaningful, but understand how decisions are made

Auditor General proposes possible reviews of new Centre for Disease Control

Faster FDA pathway approves new higher dose weight loss therapy in just 54 days

Follow Us

New Stories

The 'Dispatched' Week in Review' Podcast - 27 March

The unseen price of survival for women facing early breast cancer in Australia

This is the not so quiet demand and doctrine of rationed health care

If these can be presented as positives, then we really have become accustomed to terrible

Liberty expands into Asia Pacific life sciences insurance with new tailored offering

Budget delivers progress, but hundreds of thousands still waiting for access

To what extent does the system even see itself as bound by external review?